William Blair has high hopes for Pharmacyclics' ibrutinib

|By:, SA News Editor

William Blair is keeping expectations low for Pharmacyclics' (PCYC +1.4%) ibrutinib, saying only that the investigational BTK inhibitor "could become the largest product in hematology oncology history."

Cited in the report: The agent's potential in "almost all B-cell malignancies," its "best combined efficacy and safety profile," its first to market status, its potential to expand into more indications and move to frontline and maintenance settings from the relapsed/refractory setting, and a lack of competition.

PCYC initiated at Buy.

Price target is $143, representing a 20% upside from Monday's close.